Clinical Trial Update: This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial comparing morning versus random scheduling of standard-of-care pembrolizumab infusions for metastatic non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Metastatic Non Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING